Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
IceCure Medical
IceCure Medical Overview
IceCure Medical develops and markets minimally invasive cryoablation therapies for women's health and the general oncology market. The company's proprietary IceSense3 and ProSense systems provide minimally invasive, in-office definitive treatment for symptomatic tumors in various organs.
The procedure is done under ultrasound or CT imaging to guide a small probe (thin hollow needle) into the tumor. The system then uses extremely cold temperatures to ablate the targeted tumor in situ. The cryoablation procedure is a safe and effective treatment option that can be performed quickly in a doctor's office.
IceCure has FDA and CE approval for broad benign and malignant indications. The company's ProSense is available in the United States, Europe, Hong Kong, Thailand, Singapore, Central America, and South America. The company is also undergoing the regulatory process in China with the CFDA as well as other Asian and South American countries. It is currently participating in several clinical studies for the treatment of lung, kidney, and breast cancer (under clinical studies in the United States and Japan).
In January 2020, it was cleared by the FDA to use its tumor-freezing technology on additional types of cancers (it was already cleared for use on breast cancer patients).
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
#Customers #Investment
Mar 12, 2024
www.prnewswire.com
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
#Partners
Mar 7, 2024
www.prnewswire.com
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
#Management Changes #Expand
Mar 4, 2024
www.prnewswire.com
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
#Customers, Expand
Feb 27, 2024
www.prnewswire.com
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
#Customers #Investment
Mar 12, 2024
www.prnewswire.com
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
#Partners
Mar 7, 2024
www.prnewswire.com
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
#Management Changes #Expand
Mar 4, 2024
www.prnewswire.com
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
#Customers, Expand
Feb 27, 2024
www.prnewswire.com
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop
#Customers, Partners, Expand
View other companies you might be interested in
IceCure Medical Team
No Data, yet.
Sorry, no content found under this section.
View other companies you might be interested in
Connect with
What is the reason for connecting? *
Your company *
Company website (recommended)
Please enter a valid website
Your organization type *
Please enter a valid organization type
Your position *
Add invitation message
0/300
Sending invitation...
Invitation sent
You will be able to start a conversation once [Name] accepts it.